If Acadia/Baker Bros are looking at a purchase or take over of NEU the big question is would they wait to see phase 3 approval of 2591. That is years away.
Acadia was very successful in getting approval for Trofinitide and would be able to measure 2591 progress against its sister drug closely and accurately at every stage. This may give them confidence to move much earlier!
That is assuming NEU are being as open with sharing 2591 data with ACAD as ACAD shared Trofinitide data with NEU which was part of their agreement.
Share Price, page-5737
-
- There are more pages in this discussion • 5,063 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.90 |
Change
-0.200(1.00%) |
Mkt cap ! $2.543B | |||
| Open | High | Low | Value | Volume |
| $20.17 | $20.17 | $19.57 | $5.655M | 285.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1126 | $19.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.91 | 589 | 2 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |